Latest Conference

Mary Koslap-Petraco, DNP, PPCNP-BC, CPNP, FAANP, reacts to the recent cancelations of the ACIP and VRBPAC and comments on the potential down stream effects.

At the 2025 NAPNAP National Conference, Maureen Madden, DNP, CPNP-AC, CCRN, FCCM, FAAN, provides the key takeaways and recommendations for glycemic control guidance, updated in 2024.

The study, known as BRAVE-AA-PEDS, was sponsored by Eli Lilly and Company and involved 257 adolescents aged 12 to under 18 years.

A presentation at the 46th National Association of Pediatric Nurse Practitioners (NAPNAP) conference explored the role of biologics in pediatric care, their applications in various conditions, and safety considerations for clinicians.

The newest tapinarof results were presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting.

A quick look into some of the top sessions occurring at the NAPNAP National Conference, being held from March 10-13, 2025 in Chicago, IL.

Lebrikizumab improves itch, sleep interference, and skin pain in atopic dermatitis patients previously treated with dupilumab, offering a new treatment option.

According to data presented at AAAAI, berotralstat demonstrated a well tolerated safety profile and early and sustained reductions in monthly HAE attacks among patients aged 2 to under 12 years.

In this Q+A interview, Matthew Greenhawt, MD, breaks down a poster presentation from AAAAI / WAO joint congress meeting, highlighting increasing EoE incidence and prevalence.

In all, 51.9% of patients entered with or achieved complete disease clearance at least once during the 48-week study.

Brittany Bruggeman, MD, highlights the importance of newer, easier-to-use glucagon formulations in treating severe hypoglycemia in patients with type 1 diabetes.

HPV vaccination in Brazil led to significant reductions in genital warts and cervical precancer hospitalizations, especially among those under 20 years of age.

Panama’s switch to the 9-valent HPV vaccine promises greater protection and reduced cancer rates, preventing thousands of HPV-related cases and deaths.

Melissa Fickey, MD, explains TMS therapy for major depressive disorder, and highlights key positive data for NeuroStar TMS Therapy, which was presented at the American Academy of Child and Adolescent Psychiatry (AACAP) meeting in Seattle, Washington.

Octavio Ramilo, MD, joins us to discuss new clesrovimab phase 2b/3 study data presented at IDWeek 2024 in Los Angeles, California.

There were no treatment or RSV-related deaths during the study.

"The magnitude of benefit, trajectory of symptomatic improvement, and dependency on the number of treatment sessions showed a treatment effect similar to that found in adults," stated study authors.

The ongoing challenges of mental health, artificial intelligence, and the addressing of social determinants of health are key themes of pediatric health care are topics of discussion with Matthew Davis, MD, FAAP in this video interview.